Scholarlink

Objective <p>To develop and validate a multimodal deep learning model that predicts treatment responses to intravitreal anti-vascular endothelial growth factor (anti-VEGF) injections in patients with diabetic macular oedema (DMO) by combining optical coherence tomography images and clinical data.</p> Methods <p>This study included 107 DMO patients who received three consecutive anti-VEGF treatments. Model performance was evaluated using area under the receiver operating characteristic curve (AUROC), accuracy, sensitivity, and specificity. The model’s predictions were compared with those of retinal specialists.</p> Results <p>Among 107 patients, 65 showed good response and 42 showed poor response to treatment. The multimodal model achieved an AUROC of 0.962 (95% CI, 0.945–0.979), accuracy of 0.953 (95% CI, 0.933–0.973), sensitivity of 0.969 (95% CI, 0.951–0.987), and specificity of 0.928 (95% CI, 0.903–0.953) in the internal validation. The model outperformed retinal specialists, who achieved accuracies ranging from 0.571 to 0.857.</p> Conclusion <p>The multimodal deep learning model demonstrated high accuracy in predicting anti-VEGF treatment responses in DMO patients. This approach could enable more personalised treatment strategies and optimal resource utilisation in ophthalmological care. Further validation with larger, multicentre datasets is warranted to confirm its clinical utility.</p>

错误：搜索内容不能为空，请输入英文关键词
错误：关键词超出字数限制，请精简
高级检索

Multimodal deep learning prediction of treatment response to anti-vascular endothelial growth factor in diabetic macular oedema

  • 期刊论文

  • 发表日期：

    2026年5月6日

查看全文
  • Je Moon Yoon,
  • Sung Ho Jung,
  • Myung Jin Chung,
  • Min-Ji Kim,
  • Mi Yeon Song,
  • Kyuyeon Cho,
  • Mingui Kong,
  • Hakje Yoo,
  • Don-Il Ham

摘要

Objective

To develop and validate a multimodal deep learning model that predicts treatment responses to intravitreal anti-vascular endothelial growth factor (anti-VEGF) injections in patients with diabetic macular oedema (DMO) by combining optical coherence tomography images and clinical data.

Methods

This study included 107 DMO patients who received three consecutive anti-VEGF treatments. Model performance was evaluated using area under the receiver operating characteristic curve (AUROC), accuracy, sensitivity, and specificity. The model’s predictions were compared with those of retinal specialists.

Results

Among 107 patients, 65 showed good response and 42 showed poor response to treatment. The multimodal model achieved an AUROC of 0.962 (95% CI, 0.945–0.979), accuracy of 0.953 (95% CI, 0.933–0.973), sensitivity of 0.969 (95% CI, 0.951–0.987), and specificity of 0.928 (95% CI, 0.903–0.953) in the internal validation. The model outperformed retinal specialists, who achieved accuracies ranging from 0.571 to 0.857.

Conclusion

The multimodal deep learning model demonstrated high accuracy in predicting anti-VEGF treatment responses in DMO patients. This approach could enable more personalised treatment strategies and optimal resource utilisation in ophthalmological care. Further validation with larger, multicentre datasets is warranted to confirm its clinical utility.